Pemirolast potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats

Neuropharmacology

Volumn 46, Issue 6, 2004, Pages 888-894

  Itoh, Yoshinori ^a   Sendo, Toshiaki ^a   Hirakawa, Toshio ^b   Takasaki, Shinya ^a   Goromaru, Takeshi ^a   Nakano, Hitoo ^b   Oishi, Ryozo ^a  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Hypersensitivity; Paclitaxel; Pemirolast; Pulmonary dysfunction; Sensory nerve peptides

Indexed keywords

ANTIALLERGIC AGENT; ANTINEOPLASTIC AGENT; CALCITONIN GENE RELATED PEPTIDE; CROMOGLYCATE DISODIUM; DIPHENHYDRAMINE; FAMOTIDINE; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; KETOTIFEN; LANEPITANT; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR ANTAGONIST; NEUROKININ A; NEUROPEPTIDE; PACLITAXEL; PEMIROLAST; SAREDUTANT; SUBSTANCE P;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CONTROLLED STUDY; DRUG POTENCY; EXTRAVASATION; HYPERSENSITIVITY REACTION; LUNG LAVAGE; MALE; NONHUMAN; OXYGEN TENSION; PRIORITY JOURNAL; RAT;

ANIMALS; CALCITONIN GENE-RELATED PEPTIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG HYPERSENSITIVITY; MALE; NEUROKININ A; NEUROPEPTIDES; PACLITAXEL; PYRIDINES; PYRIMIDINONES; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANCE P;

EID: 1642291725     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2003.11.018     Document Type: Article

References (33)

1. Bitton R.J., Figg W.D., Reed E.A. Preliminary risk-benefit assessment of paclitaxel. Drug Safety. 12:1995;196-208.
2. Boehm D.K., Maksymiuk A.W. Paclitaxel premedication regimens. Journal of National Cancer Institution. 88:1996;463-465.
3. Bookman M.A., Kloth D.D., Kover P.E., Smolinski S., Ozols R.F. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Annual Oncology. 8:1997;611-614.
4. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry. 72:1976;248-254.
5. 1 receptor antagonists in the anaesthetized rat. European Journal of Pharmacology. 318:1996;377-385.
6. Cormio G., Di Vagno G., Melilli G.A., Cazzolla A., Di Gesu G., Carriero C., Cramarossa D., Loverro G., Selvaggi L. Hypersensitivity reactions in ovarian cancer patients receiving paclitaxel. Journal of Chemotherapy. 11:1999;407-409.
7. Crossman D.C., Dashwood M.R., Taylor G.W., Wellings R., Fuller R.W. Sodium cromoglycate: evidence of tachykinin antagonist activity in the human skin. Journal of Applied Physiology. 5:1993;167-172.
8. 2) receptor. Life Science. 50:1992;101-106.
9. Holzer P. Local effector functions of capsaicin-sensitive sensory nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. Neuroscience. 24:1988;739-768.
10. Kris M.G., O'Connell J.P., Gralla R.J., Wertheim M.S., Parente R.M., Schiff P.B., Young C.W. Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treatment Report. 70:1986;605-607.
11. Kwon J.S., Elit L., Finn M., Hirte H., Mazurka J., Moens F., Trim K. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. Gynecological Oncology. 84:2002;420-425.
12. Lai Y.L., Lee S.P. Mediators in hyperpnea-induced bronchoconstriction of guinea pigs. Naunyn-Schmiedebergs Archives of Pharmacology. 360:1999;597-602.
13. Lorenz W., Reimann H.J., Schmal A., Dormann P., Schwarz B., Neugebauer E., Doenicke A. Histamine release in dogs by Cremophor E1 and its derivatives: oxethylated oleic acid is the most effective constituent. Agents and Actions. 7:1997;63-67.
14. Lundberg J.M., Franco-Cereceda A., Hua X.Y., Hökfelt T., Fischer J.A. Co-existence of substance P and calcitonin gene-related peptide immunoreactivities in sensory nerves in relation to cardiovascular and bronchoconstrictor effects of capsaicin. European Journal of Pharmacology. 108:1985;315-319.
15. Markman M., Kennedy A., Webster K., Kulp B., Peterson G., Belinson J. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. Journal of Clinical Oncology. 18:2000;102-105.
16. Markman M., Kennedy A., Webster K., Peterson G., Kulp B., Belinson J. An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. Journal of Cancer Research and Clinical Oncology. 125:1999;427-429.
17. Martling C.R. Sensory nerves containing tachykinins and CGRP in the lower airways. Functional implications for bronchoconstriction, vasodilation and protein extravasation. Acta Physiologica Scandinavica. 563:1987;1-57.
18. Martin U., Römer D. The pharmacological properties of a new, orally active antianaphylactic compound: ketotifen, a benzocycloheptathiophene. Arzneimittel-Forshung Drug Research. 28:1978;770-782.
19. Miller P., James G.W. Inhibition of experimental immediate hypersensitivity reactions by a novel xanthone, RU 31156. Archives Internationales et de Pharmacodynamie et Therapie. 231:1978;328-339.
20. Norris A.A., Leeson M.E., Jackson D.M., Holroyde M.C. Modulation of neurogenic inflammation in rat trachea. Pulmonary Pharmacology. 3:1990;180-184.
21. Nuijen B., Bouma M., Schellens J.H., Beijnen J.H. Progress in the development of alternative pharmaceutical formulations of taxanes. Investive New Drugs. 19:2001;143-153.
22. Olson J.K., Sood A.K., Sorosky J.I., Anderson B., Buller R.E. Taxol hypersensitivity: rapid retreatment is safe and cost effective. Gynecological Oncology. 68:1998;25-28.
23. Rogers D.F., Belvisi M.G., Aursudkij B., Evans T.W., Barnes P.J. Effects and interactions of sensory neuropeptides on airway microvascular leakage in guinea-pigs. British Journal of Pharmacology. 95:1988;1109-1116.
24. Rodger I.W., Tousignant C., Young D., Savoie C., Chan C.C. Neurokinin receptors subserving plasma extravasation in guinea pig airways. Canadian Journal of Physiology and Pharmacology. 73:1995;927-931.
25. Rowinsky E.K., Donehower R.C. Paclitaxel (taxol). New England Journal of Medicine. 332:1995;1004-1014.
26. Sendo T., Itoh Y., Goromaru T., Sumimura T., Saito M., Aki K., Yano T., Oishi R. A potent tryptase inhibitor nafamostat mesilate dramatically suppressed pulmonary dysfunction induced in rats by a radiographic contrast medium. British Journal of Pharmacology. 138:2003;959-967.
27. Sendo T., Kataoka Y., Takeda Y., Furuta W., Oishi R. Nitric oxide protects against contrast media-increased pulmonary vascular permeability in rats. Investigative Radiology. 35:2000;472-478.
28. 1 receptors in the guinea-pig lung, using selective radioligands. European Journal of Pharmacology. 311:1996;177-186.
29. Walker F.E. Paclitaxel (TAXOL): side effects and patient education issues. Seminar Oncology and Nursing. 9:(Suppl.):1993;6-10.
30. Weiss R.B., Donehower R.C., Wiernik P.H., Ohnuma T., Gralla R.J., Trump D.L., Baker J.R. Jr., Van Echo D.A., Von Hoff D.D., Leyland-Jones B. Hypersensitivity reactions from taxol. Journal of Clinical Oncology. 8:1990;1263-1268.
31. Wiernik P.H., Schwartz E.L., Strauman J.J., Dutcher J.P., Lipton R.B., Paietta E. Phase I clinical and pharmacokinetic study of taxol. Cancer Research. 47:1987;2486-2493.
32. Yamawaki I., Tamaoki J., Takeda Y., Nagai A. Inhaled cromoglycate reduces airway neurogenic inflammation via tachykinin antagonism. Research Communication Molecular Pathology and Pharmacology. 98:1997;265-272.
33. Yanagihara Y., Kasai H., Matsui S., Ninomiya K. Immunopharmacological studies on TBX, a new antiallergic drug (3). Inhibitory effects on histamine release from lung fragments and bronchoconstriction in guinea pigs. Japanese Journal of Pharmacology. 51:1989;83-92.